Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Endocrinology 3, 450–451 (1 June 2007) | doi:10.1038/ncpendmet0512
Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?
&
Abstract
Charbonnel B et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29: 2638–2643 Synopsis Background Although multiple therapeutic options are available for type 2 diabetes mellitus (T2DM), a large number of patients are unable to achieve, or maintain, glycemic control.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
